Friday, April 26, 2019 5:36:44 PM
Some figures to help out those who say this is worth nothing
If I remember right the report* said $400 exclusive market year one and adding $100 million per year to 2027 where it is estimated to be $1.3 billion. As we're not in year 1 since we have no drug - yet, I moved it to 2020 as year one with, the advance in market going up as per the rationale of the report. (All figures in USD not CD unless specified)
You can adjust the start time or years with completion but I'm just trying to show what kind of money we're talking about here.
2018 $
2019 $
2020 $ 600,000,000
2021 $ 700,000,000
2022 $ 800,000,000
2023 $ 900,000,000
2024 $1,000,000,000
2025 $1,100,000,000
2026 $1,200,000,000
2027 $1,300,000,000
Total $7,600,000,000 ($10,133,000,000 CD) over 8 years or $1.4 billion($1.86 CD) per year average. I'm no rocket scientist but with an exclusive market like that and present shares outstanding of 304 million at cap of $18 million, assuming fifty percent profit brings us to a profit of $12.5 per share ($16.6 CD) over that period.
Or, if it's 75% profit then share profit is $18.75 ($25 CD) Average over 8 years and it's $2.34 ($3.12 CD) per share.
In any case, if anybody is worried about dilution, as long as it's helping us get to the start line it's fine with me.
Of course, what do I know, I might be missing something here or, maybe missing everything. Any experts want to chime in?
*"The commercial opportunity for Kalytera’s CBD products for the prevention and treatment of GVHD is large. According to the January 2018 Market Forecast Report by DelveInsight Perspective, the potential market for a successful product for prevention and treatment of GVHD in the 7 major jurisdictions (the U.S., Germany, France, Italy, Spain, the U.K. and Japan) is estimated to be more than USD $408 million in 2018, and could grow to approximately USD $1.3 billion by 2027."
Read more at https://stockhouse.com/companies/bullboard?symbol=kaltf&postid=29590536#dfG0gd8Md272guYF.99
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM